513 related articles for article (PubMed ID: 24631081)
1. Duration of vaccine efficacy against malaria: 5th year of follow-up in children vaccinated with RTS,S/AS02 in Mozambique.
Campo JJ; Sacarlal J; Aponte JJ; Aide P; Nhabomba AJ; Dobaño C; Alonso PL
Vaccine; 2014 Apr; 32(19):2209-16. PubMed ID: 24631081
[TBL] [Abstract][Full Text] [Related]
2. Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial.
Aide P; Dobaño C; Sacarlal J; Aponte JJ; Mandomando I; Guinovart C; Bassat Q; Renom M; Puyol L; Macete E; Herreros E; Leach A; Dubois MC; Demoitie MA; Lievens M; Vekemans J; Loucq C; Ballou WR; Cohen J; Alonso PL
Vaccine; 2011 Aug; 29(35):6059-67. PubMed ID: 21443960
[TBL] [Abstract][Full Text] [Related]
3. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial.
Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Aide P; Sigauque B; Milman J; Mandomando I; Bassat Q; Guinovart C; Espasa M; Corachan S; Lievens M; Navia MM; Dubois MC; Menendez C; Dubovsky F; Cohen J; Thompson R; Ballou WR
Lancet; 2005 Dec; 366(9502):2012-8. PubMed ID: 16338450
[TBL] [Abstract][Full Text] [Related]
4. Sequential Phase 1 and Phase 2 randomized, controlled trials of the safety, immunogenicity and efficacy of combined pre-erythrocytic vaccine antigens RTS,S and TRAP formulated with AS02 Adjuvant System in healthy, malaria naïve adults.
Kester KE; Gray Heppner D; Moris P; Ofori-Anyinam O; Krzych U; Tornieporth N; McKinney D; Delchambre M; Ockenhouse CF; Voss G; Holland C; Beckey JP; Ballou WR; Cohen J;
Vaccine; 2014 Nov; 32(49):6683-91. PubMed ID: 24950358
[TBL] [Abstract][Full Text] [Related]
5. Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial.
Aide P; Aponte JJ; Renom M; Nhampossa T; Sacarlal J; Mandomando I; Bassat Q; Manaca MN; Leach A; Lievens M; Vekemans J; Dubois MC; Loucq C; Ballou WR; Cohen J; Alonso PL
PLoS One; 2010 Nov; 5(11):e13838. PubMed ID: 21079803
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children.
Sacarlal J; Aide P; Aponte JJ; Renom M; Leach A; Mandomando I; Lievens M; Bassat Q; Lafuente S; Macete E; Vekemans J; Guinovart C; Sigaúque B; Sillman M; Milman J; Dubois MC; Demoitié MA; Thonnard J; Menéndez C; Ballou WR; Cohen J; Alonso PL
J Infect Dis; 2009 Aug; 200(3):329-36. PubMed ID: 19569964
[TBL] [Abstract][Full Text] [Related]
7. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of Research.
Kester KE; Cummings JF; Ockenhouse CF; Nielsen R; Hall BT; Gordon DM; Schwenk RJ; Krzych U; Holland CA; Richmond G; Dowler MG; Williams J; Wirtz RA; Tornieporth N; Vigneron L; Delchambre M; Demoitie MA; Ballou WR; Cohen J; Heppner DG;
Vaccine; 2008 Apr; 26(18):2191-202. PubMed ID: 18387719
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial.
Bojang KA; Milligan PJ; Pinder M; Vigneron L; Alloueche A; Kester KE; Ballou WR; Conway DJ; Reece WH; Gothard P; Yamuah L; Delchambre M; Voss G; Greenwood BM; Hill A; McAdam KP; Tornieporth N; Cohen JD; Doherty T;
Lancet; 2001 Dec; 358(9297):1927-34. PubMed ID: 11747915
[TBL] [Abstract][Full Text] [Related]
9. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection.
Kester KE; Cummings JF; Ofori-Anyinam O; Ockenhouse CF; Krzych U; Moris P; Schwenk R; Nielsen RA; Debebe Z; Pinelis E; Juompan L; Williams J; Dowler M; Stewart VA; Wirtz RA; Dubois MC; Lievens M; Cohen J; Ballou WR; Heppner DG;
J Infect Dis; 2009 Aug; 200(3):337-46. PubMed ID: 19569965
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial.
Alonso PL; Sacarlal J; Aponte JJ; Leach A; Macete E; Milman J; Mandomando I; Spiessens B; Guinovart C; Espasa M; Bassat Q; Aide P; Ofori-Anyinam O; Navia MM; Corachan S; Ceuppens M; Dubois MC; Demoitié MA; Dubovsky F; Menéndez C; Tornieporth N; Ballou WR; Thompson R; Cohen J
Lancet; 2004 Oct 16-22; 364(9443):1411-20. PubMed ID: 15488216
[TBL] [Abstract][Full Text] [Related]
11. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial.
Aponte JJ; Aide P; Renom M; Mandomando I; Bassat Q; Sacarlal J; Manaca MN; Lafuente S; Barbosa A; Leach A; Lievens M; Vekemans J; Sigauque B; Dubois MC; Demoitié MA; Sillman M; Savarese B; McNeil JG; Macete E; Ballou WR; Cohen J; Alonso PL
Lancet; 2007 Nov; 370(9598):1543-51. PubMed ID: 17949807
[TBL] [Abstract][Full Text] [Related]
12. A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults.
Cummings JF; Polhemus ME; Kester KE; Ockenhouse CF; Gasser RA; Coyne P; Wortmann G; Nielsen RK; Schaecher K; Holland CA; Krzych U; Tornieporth N; Soisson LA; Angov E; Heppner DG;
Vaccine; 2024 Apr; 42(12):3066-3074. PubMed ID: 38584058
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of the RTS,S/AS01E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial.
Asante KP; Abdulla S; Agnandji S; Lyimo J; Vekemans J; Soulanoudjingar S; Owusu R; Shomari M; Leach A; Jongert E; Salim N; Fernandes JF; Dosoo D; Chikawe M; Issifou S; Osei-Kwakye K; Lievens M; Paricek M; Möller T; Apanga S; Mwangoka G; Dubois MC; Madi T; Kwara E; Minja R; Hounkpatin AB; Boahen O; Kayan K; Adjei G; Chandramohan D; Carter T; Vansadia P; Sillman M; Savarese B; Loucq C; Lapierre D; Greenwood B; Cohen J; Kremsner P; Owusu-Agyei S; Tanner M; Lell B
Lancet Infect Dis; 2011 Oct; 11(10):741-9. PubMed ID: 21782519
[TBL] [Abstract][Full Text] [Related]
14. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial.
Sacarlal J; Aponte JJ; Aide P; Mandomando I; Bassat Q; Guinovart C; Leach A; Milman J; Macete E; Espasa M; Ofori-Anyinam O; Thonnard J; Corachan S; Dubois MC; Lievens M; Dubovsky F; Ballou WR; Cohen J; Alonso PL
Vaccine; 2008 Jan; 26(2):174-84. PubMed ID: 18069097
[TBL] [Abstract][Full Text] [Related]
15. Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens.
Campo JJ; Dobaño C; Sacarlal J; Guinovart C; Mayor A; Angov E; Dutta S; Chitnis C; Macete E; Aponte JJ; Alonso PL
PLoS One; 2011; 6(10):e25779. PubMed ID: 22022448
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique.
Macete E; Aponte JJ; Guinovart C; Sacarlal J; Ofori-Anyinam O; Mandomando I; Espasa M; Bevilacqua C; Leach A; Dubois MC; Heppner DG; Tello L; Milman J; Cohen J; Dubovsky F; Tornieporth N; Thompson R; Alonso PL
Trop Med Int Health; 2007 Jan; 12(1):37-46. PubMed ID: 17207146
[TBL] [Abstract][Full Text] [Related]
17. Mosquirix (RTS,S): a novel vaccine for the prevention of Plasmodium falciparum malaria.
Wilby KJ; Lau TT; Gilchrist SE; Ensom MH
Ann Pharmacother; 2012 Mar; 46(3):384-93. PubMed ID: 22408046
[TBL] [Abstract][Full Text] [Related]
18. Randomized, controlled trial of the long term safety, immunogenicity and efficacy of RTS,S/AS02(D) malaria vaccine in infants living in a malaria-endemic region.
Abdulla S; Salim N; Machera F; Kamata R; Juma O; Shomari M; Kubhoja S; Mohammed A; Mwangoka G; Aebi T; Mshinda H; Schellenberg D; Carter T; Villafana T; Dubois MC; Leach A; Lievens M; Vekemans J; Cohen J; Ballou WR; Tanner M
Malar J; 2013 Jan; 12():11. PubMed ID: 23297680
[TBL] [Abstract][Full Text] [Related]
19. Five-year safety and immunogenicity of GlaxoSmithKline's candidate malaria vaccine RTS,S/AS02 following administration to semi-immune adult men living in a malaria-endemic region of The Gambia.
Bojang K; Milligan P; Pinder M; Doherty T; Leach A; Ofori-Anyinam O; Lievens M; Kester K; Schaecher K; Ballou WR; Cohen J
Hum Vaccin; 2009 Apr; 5(4):242-7. PubMed ID: 19276646
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of the RTS,S/AS01 malaria vaccine and implications for duration of vaccine efficacy: secondary analysis of data from a phase 3 randomised controlled trial.
White MT; Verity R; Griffin JT; Asante KP; Owusu-Agyei S; Greenwood B; Drakeley C; Gesase S; Lusingu J; Ansong D; Adjei S; Agbenyega T; Ogutu B; Otieno L; Otieno W; Agnandji ST; Lell B; Kremsner P; Hoffman I; Martinson F; Kamthunzu P; Tinto H; Valea I; Sorgho H; Oneko M; Otieno K; Hamel MJ; Salim N; Mtoro A; Abdulla S; Aide P; Sacarlal J; Aponte JJ; Njuguna P; Marsh K; Bejon P; Riley EM; Ghani AC
Lancet Infect Dis; 2015 Dec; 15(12):1450-8. PubMed ID: 26342424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
